AUSTIN, Texas – July 28, 2021 – Altogen Labs offers over 100 validated models of cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), including syngeneic xenograft models. Xenograft IND testing services are performed to measure the activity and efficacy of novel anti-cancer compounds based on the rate of engrafted tumor growth. The most recent additions… Continue Reading
AUSTIN, Texas – October 18, 2022 – An orthotopic glioblastoma xenograft model developed by Altogen Labs has been adopted as the reference in vivo platform for validating tissue-targeted nucleic acid delivery, as documented in published technical materials for nanoparticle-based in vivo transfection reagents. In the referenced validation work, nanoparticle-conjugated RNA and DNA complexes were administered… Continue Reading
Sodium dichloroacetate (DCA) has been investigated as a novel cancer therapy since 2007 when Bonnet et al published research study demonstrating the efficacy of DCA in treating human cancers by inhibition of mitochondrial pyruvate dehydrogenase kinase (PDK). Altogen Labs, an Austin-based biotechnology and preclinical research company, performed an independent study exploring potential novel and accessible… Continue Reading
AUSTIN, Texas – August 22, 2022 – Altogen Labs today detailed its in vivo toxicology service in mouse and rat, covering LD50 determination and acute, sub-chronic, and chronic safety assessment for investigational compounds. Toxicology defines the therapeutic window, and the therapeutic window defines whether a program is viable. A compound with excellent efficacy at a… Continue Reading
Testing the anticancer efficacy of a plant extract involves a series of in vitro (using cancer cell lines) and in vivo (animal-based) experiments, as well as testing safety and efficacy. The process can be lengthy and requires adherence to scientific and ethical guidelines. Here is an outline of the general procedure: Altogen Labs provides commercially… Continue Reading
AUSTIN, Texas – March 3, 2022 – Altogen Labs has expanded its in-house validated tumor model collection to 115 cell line-derived xenograft (CDX) models, 30 patient-derived xenograft (PDX) models, and over 40 syngeneic models, following the addition of seven newly validated models: A549, BT474, HUH7, MDA-MB-231, MKN-74, NCI-N87, and PC-3. Model breadth is not a… Continue Reading
AUSTIN, Texas – February 24, 2022 – Altogen Labs today highlighted publicly available client referrals from Savara Pharmaceuticals and Terapio Corporation, both of which have gone on record describing their experience working with the Austin-based preclinical CRO. The company today offers over 120 in-house validated CDX and PDX animal models for xenograft efficacy studies, alongside syngeneic… Continue Reading
AUSTIN, Texas – December 14, 2021 – Altogen Labs today detailed its tetracycline-inducible RNAi knockdown cell line development service, giving researchers temporal control over gene silencing in target validation studies. Constitutive knockdown has a well-known limitation. If the target gene is essential, cells carrying a stable knockdown construct either die or adapt, and the surviving… Continue Reading
AUSTIN, Texas – September 21, 2021 – Altogen Labs today detailed its validated gastric cancer xenograft collection, comprising seven in-house validated models spanning the molecular subtypes that define modern gastric cancer development. Gastric cancer is among the leading causes of cancer mortality worldwide and among the most molecularly heterogeneous. Programs targeting HER2, MET, FGFR2, and… Continue Reading
AUSTIN, Texas – August 10, 2021 – A preclinical study performed by Altogen Labs has demonstrated functional delivery of small RNA and plasmid DNA across the blood-brain barrier into glioblastoma tissue, a result announced publicly in July 2021 and one of the more difficult delivery problems in neuro-oncology drug development. The blood-brain barrier remains the… Continue Reading
Email Us
Call Us